XOMA News and Press, XOMA Royalty Corporation From 05/14/26

Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Share...

Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. ...

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Sha...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation PR Newswire NEW YORK , April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of director...

Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. ...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options a...

2026-04-27 07:32:03 ET More on Ligand Pharmaceuticals, XOMA XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model Ligand Pharmaceuticals Incorporated 2025 Q4 - Results...

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden ...

2026-04-27 06:27:23 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model Ligand Pharmaceuticals Incorporated 2025 Q4 - Results - Earnings Call Presentation Ligand Pharmaceuticals Incorporated (LGND...

2026-03-31 07:35:00 ET Co-authored with Hidden Opportunities You've had those days when you start early, jump straight into solving problems, putting out fires, and juggling deadlines, and before you know it, it's dark outside. It was no doubt a productive day; you got things do...